Relmada Therapeutics
RLMD
95 hedge funds and large institutions have $39.7M invested in Relmada Therapeutics in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 35 reducing their positions, and 14 closing their positions.
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
4% more funds holding
Funds holding: 91 → 95 (+4)
2% less capital invested
Capital invested by funds: $40.3M → $39.7M (-$652K)
5.6% less ownership
Funds ownership: 59.11% → 53.52% (-5.6%)
34% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 35
81% less call options, than puts
Call options by funds: $271K | Put options by funds: $1.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$578K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$552K |
| 3 |
RC
RBF Capital
San Francisco,
California
|
+$537K |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$526K |
| 5 |
PCM
Parsons Capital Management
Providence,
Rhode Island
|
+$418K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.41M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.17M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$741K |
| 4 |
Walleye Capital
New York
|
-$593K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$539K |
RLMD Hedge Fund Activity: Q2 2023 in Review
95 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q2 2023, worth a combined $39.7M — down 1.6% from $40.3M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RLMD positions and 14 closed out — a net gain of 4 holders — while 23 added to existing stakes and 35 trimmed.
The largest buyer was GSA Capital Partners, adding an estimated $578K. The largest seller was BlackRock, cutting an estimated $3.41M.
- 95 institutional investors held Relmada Therapeutics (RLMD) as of Q2 2023, up from 91 in Q1 2023.
- Funds reported $39.7M of Relmada Therapeutics stock for Q2 2023, down 1.6% quarter-over-quarter.
- 18 funds opened new Relmada Therapeutics positions in Q2 2023 and 14 closed out, a net change of +4 holders.
- The largest Relmada Therapeutics buyer in Q2 2023 was GSA Capital Partners, an estimated $578K added.
- The largest Relmada Therapeutics seller in Q2 2023 was BlackRock, an estimated $3.41M sold.
Based on aggregated 13F filings for Q2 2023.